Sarepta expands gene therapy toolkit, bets $72.5M to hitch a ride on Codiak's exosome tech

Adding another type of duel to its gene therapy engine, Sarepta has signed Codiak Biosciences as a partner to explore re-dosing of its signature precision medicines for neuromuscular disorders.